MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Agendia
Sponsor:
Collaborators:
University of South Florida
University of Miami
Morton Plant Mease Health Care
Helen Ellis Memorial Hospital
Texas Health Plano Cancer Institute
Ohio State University Comprehensive Cancer Center
University of Oklahoma
Eastchester Center for Cancer Care
University of Southern Alabama
Information provided by (Responsible Party):
Agendia
ClinicalTrials.gov Identifier:
NCT01501487
First received: December 22, 2011
Last updated: October 15, 2014
Last verified: October 2014

December 22, 2011
October 15, 2014
October 2011
December 2015   (final data collection date for primary outcome measure)
  • Determine the predictive power of chemosensitivity of MammaPrint as measured by pCR. [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]
  • Determine the predictive power of chemosensitivity of the combination of MammaPrint and BluePrint as measured by pCR. [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]
Difference in response rate in the molecular subtype categories. [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01501487 on ClinicalTrials.gov Archive Site
  • Compare TargetPrint single gene read out of ER, PR and HER2 with local and centralized IHC and/or CISH/FISH assessment of ER, PR and HER2. [ Time Frame: Baseline. First study visit. ] [ Designated as safety issue: No ]
  • Identify possible correlations between the TheraPrint Research Gene Panel outcomes and chemoresponsiveness. [ Time Frame: 6-9 months ] [ Designated as safety issue: No ]
  • Identify and/or validate predictive gene expression profiles of clinical response/resistance to chemotherapy. [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]
  • Compare the three BluePrint molecular subtype categories with IHC-based subtype classification. [ Time Frame: Baseline. First study visit. ] [ Designated as safety issue: No ]
  • Difference between single gene read out of ER, PR and HER2 and local and centralized immunohistochemistry (IHC) and/or CISH/FISH assessment of ER, PR and HER2. [ Time Frame: Baseline. First study visit. ] [ Designated as safety issue: No ]
  • Identification and/or validation of predictive gene expression profiles of clinical response/resistance to chemotherapy. [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]
  • Response rate of TheraPrint Research Gene Panel. [ Time Frame: 6-9 months ] [ Designated as safety issue: No ]
  • Difference between molecular subtype classification (BluePrint) and immunohistochemistry based subtype classification. [ Time Frame: Baseline. First study visit. ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (LABC).

Patients with suspected primary breast cancer on mammography and clinical examination will be assessed for eligibility by having a needle core biopsy to confirm invasive carcinoma.

A fresh unfixed tumor specimen, incisional or core biopsy will be sent to Agendia to determine the MammaPrint risk profile, the BluePrint molecular subtyping profile, the TargetPrint ER, PR and HER2 single gene readout, the 56-geneTheraPrint Research Gene Panel and the additional genes as measured on the whole genome (44k) array.

Surgical Protocol:

  1. Determination of nodal status:

    • For clinically node-negative patients: Axillary ultra sound, followed by Sentinel Lymph Node (SLN) biopsy
    • For clinically node-positive patients: ultra sound-guided Fine Needle Aspirate (FNA), followed by core biopsy
  2. Neo-adjuvant chemotherapy
  3. Definitive surgery:

    • For node-positive patients: lumpectomy, repeat SLN biopsy, Axillary Lymph Node Dissection (ALND)
    • For node-negative patients: lumpectomy, repeat SLN biopsy (optional), no ALND

Response will be measured by pathological Complete Response (pCR) and by centrally assessed Residual Cancer Burden (RCB).

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Breast Cancer
  • Drug: TAC chemotherapy
    Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
  • Drug: TC chemotherapy
    Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
  • Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
    Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
  • Drug: TCH chemotherapy
    Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
  • Drug: T + trastuzumab followed by CEF + trastuzumab

    Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.

    Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr

  • Drug: Dose dense AC followed by T + trastuzumab

    Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).

    Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.

  • Drug: Dose dense AC followed by T + trastuzumab + pertuzumab
    Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
  • Drug: PTH followed by dose dense AC of FEC

    Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,

    Followed by 4 cycles of AC or FEC:

    AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles

    In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel.

  • Active Comparator: HER2 negative patients

    In order to provide some consistency in management and have a treatment policy in place only recommended therapy with several well accepted and presumed equivalent chemotherapy regimens will be used. The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients include:

    1. TAC chemotherapy
    2. TC chemotherapy
    3. Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
    Interventions:
    • Drug: TAC chemotherapy
    • Drug: TC chemotherapy
    • Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
  • Active Comparator: Her2 positive patients
    The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients is TCH chemotherapy.
    Interventions:
    • Drug: TCH chemotherapy
    • Drug: T + trastuzumab followed by CEF + trastuzumab
    • Drug: Dose dense AC followed by T + trastuzumab
    • Drug: Dose dense AC followed by T + trastuzumab + pertuzumab
    • Drug: PTH followed by dose dense AC of FEC
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
226
December 2015
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women with histologically proven invasive breast cancer and no distant metastases and;
  • Lymphnode negative and a clinical tumor classification of T2 (≥3.5cm)-T4 or with 1-3 positive lymph nodes and a clinical tumor classification of T2-T4 DCIS or LCIS are allowed in addition to invasive cancer at T2 or T3 level.
  • Age ≥ 18 years.
  • At least one lesion that can be accurately measured in two dimensions utilizing mammogram, ultrasound, or MRI images to define specific size and validate complete pathologic response.
  • Adequate bone marrow reserves (neutrophil count >1.5 x109 /l and platelet count >100 x109/l), adequate renal function (serum creatinine ≤ 1.5 x upper limit of normal) and hepatic function (ALAT, ASAT ≤ 2.5 x upper limit of normal, alkaline phosphatase ≤ 2.5 x upper limit of normal and total bilirubin ≤ 2.0 x upper limit of normal).
  • Signed informed consent of the patient

Exclusion Criteria:

  • Any patient with confirmed metastatic disease. Patients with inflammatory breast cancer.
  • Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails Quality Assurance or Quality Control criteria.
  • Patients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for the treatment of breast cancer.
  • Any serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease.
Female
18 Years and older
No
Contact: Erin B Yoder, MS erin.yoder@agendia.com
Contact: Lisette Stork, MSc lisette.stork@agendia.com
United States
 
NCT01501487
P0334
No
Agendia
Agendia
  • University of South Florida
  • University of Miami
  • Morton Plant Mease Health Care
  • Helen Ellis Memorial Hospital
  • Texas Health Plano Cancer Institute
  • Ohio State University Comprehensive Cancer Center
  • University of Oklahoma
  • Eastchester Center for Cancer Care
  • University of Southern Alabama
Principal Investigator: Charles E Cox, MD University of South Florida
Agendia
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP